Organic Chemical – Page 50

AstraZeneca’s Lynparza Demonstrates Nearly 50% Response in Advanced Breast Cancer Patients: #AACR24 Update

1 year ago talkbio0Tagged 50, AACR24, advanced breast cancer, AstraZeneca, Frequency of Responses, Inhibitor, Lynparza, olaparib, PARP1 gene

AstraZeneca, Lynparza (olaparib), PARP inhibitor, Advanced breast cancer, 50% response rate, AACR24

Expansion of Pluvicto Use Sought by Novartis Following Positive Prostate Cancer Study Update

1 year ago talkbio0Tagged Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, Novartis, Pluvicto, Progression-Free Survival, PSMAfore trial, Radiographic, rPFS

Novartis, Pluvicto, Broader use, Prostate cancer, PSMAfore trial, Radiographic progression-free survival (rPFS), Metastatic castration-resistant prostate cancer (mCRPC)

Sanofi Settles 4,000 Zantac Cancer Lawsuits, Faces Delaware Claims

1 year ago talkbio0Tagged Claims, Daubert, Delaware, Delaware Superior Court, lawsuits, sanofi, Settlement and Resettlement, Zantac

Sanofi, Zantac, Cancer Lawsuits, Settlement, Delaware Claims, 4/000 Lawsuits, Delaware Superior Court, Daubert Ruling

Sanofi Resolves 4,000 Zantac Cancer Claims in US State Courts

1 year ago talkbio0Tagged Cancer Lawsuits, Heartburn Drug, sanofi, US State Courts, Zantac

Sanofi, Zantac, Heartburn Drug, Cancer Lawsuits, Settlement Agreement, US State Courts

Delaware Judge Rules in Favor of Roivant Subsidiary Arbutus in COVID-19 Vaccine Patent Dispute with Moderna

1 year ago talkbio0Tagged Arbutus Biopharma, claim, COVID-19 Vaccines, Judge Mitchell Goldberg, Lipid Nanoparticles, Moderna, Patent infringement, Roivant Sciences

Moderna, Arbutus Biopharma, Roivant Sciences, COVID-19 vaccine, Patent infringement, Judge Mitchell Goldberg, Lipid nanoparticles (LNP), Claim construction order

Basilea Secures FDA Approval for Zevtera to Treat Three Types of Bacterial Infections

1 year ago talkbio0Tagged ABSSSI, Acute bacterial skin, Approved, Bacteremia due to Staphylococcus aureus, Basilea Pharmaceutica, CABP, ceftobiprole, Community-acquired bacterial pneumonia, designations, exclusivity, Priority Review, QIDP, Qualified Infectious Disease Product, skin structure infections, Track/, United States Food and Drug Administration, year, Zevtera

Basilea Pharmaceutica, Zevtera (ceftobiprole), FDA approval, Acute bacterial skin and skin structure infections (ABSSSI), Staphylococcus aureus bacteremia (SAB), Community-acquired bacterial pneumonia (CABP), Qualified Infectious Disease Product (QIDP) status, Priority Review/ Fast Track/ and QIDP designations, Ten years of exclusivity in the US

Vanda’s Fanapt Secures Second FDA Approval for Treating Bipolar I Disorder

1 year ago talkbio0Tagged acute, Bipolar I disorder, Dentatorubral-Pallidoluysian Atrophy, Fanapt, iloperidone, Manic, mixed episodes, United States Food and Drug Administration, Vanda Pharmaceuticals

Fanapt, Vanda Pharmaceuticals, Bipolar I Disorder, Second FDA Nod, Iloperidone, Acute Treatment of Manic or Mixed Episodes

Bristol Myers Squibb’s KRAZATI Confirmed Effective in Pivotal Phase 3 KRYSTAL-12 Trial Following Accelerated Approval

1 year ago talkbio0Tagged Accelerated Approval, adagrasib, Approved, bristol-myers, Clinical Benefit, Confirmatory Trial, Continuous, June 21/ 2024, KRASG12C mutation, KRAZATI, KRYSTAL-12, Locally, Metastatic to, Non-Small Cell Lung Carcinoma, ORR, Overall response rate, PDUFA, Primary Endpoint, Progression-Free Survival, squibb, United States Food and Drug Administration, Verification of Theories

Bristol Myers Squibb, KRAZATI (adagrasib), Pivotal Phase 3 trial, KRYSTAL-12 study, Primary endpoint met, Progression-free survival (PFS), Overall response rate (ORR), Confirmatory trial, Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, KRASG12C mutation, Accelerated approval, Continued approval contingent on clinical benefit verification, FDA assigned PDUFA goal date of June 21/ 2024

Bristol Myers Squibb’s Zeposia Misses Mark in Phase 3 Crohn’s Disease Study

1 year ago talkbio0Tagged bristol-myers, Clinical Remission Endpoint Not, Crohn Disease, ozanimod, Unmet Medical Need, YELLOWSTONE Program, Zeposia

Bristol Myers Squibb, Zeposia (ozanimod), Phase 3 Trial Setback, Crohn’s Disease, Clinical Remission Endpoint Not Met, YELLOWSTONE Program, Unmet Medical Need in Crohn’s Treatment

Medicare Coverage Gap Linked to Reduced Prescription Rates for GLP-1 Weight Loss Drugs

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Health Care Costs, liraglutide, Lower prescription rates, Medicare, Mounjaro, Obesity, Saxenda, semaglutide, tirzepatide, Truveta study, Wegovy

GLP-1 drugs, Medicare coverage gap, Lower prescription rates, Obesity treatment, Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda), Healthcare costs, Truveta study